Ricerfarma is a dynamic young company, founded by a working group with 30 years' experience in the pharmaceutical industry.

The company recently developed a patented product line for the treatment of periodontal disease, consisting of high molecular weight (HMW) hyaluronic acid produced by a biotechnology method.

The company, which has a modern, flexible organisational structure, relies on a network of collaborators for scientific updates and constant product research.

The properties of hyaluronic acid are well known in the treatment of numerous disorders, but its use in the treatment of gum disease is highly innovative.

Ricerfarma has decided to promote this new frontier of research.

It is currently developing an international program for the introduction of the line in the major countries of the world.

Ricerfarma handles contacts and coordinates the manufacture and distribution of the product through a network of distributors.